Business
We are building towards 5 this goal with a planned succession of FDA-cleared indications, targeting existing and nascent markets.
CapsoVision, Inc: Revenue grew 15.3% to $13.55M from $11.76M. Net loss widened to $25.32M from $19.9M. Free cash flow outflow widened to $22.95M from $20.24M. Operating margin contracted 1883 bps to -188.25%. CapsoVision, Inc's annual comparison also shows free cash flow declined despite revenue growth; stock compensation grew faster than revenue; the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 15.3% to $13.55M from $11.76MOK
- Profitability — Net loss widened to $25.32M from $19.9MWatch
- Cash flow — Free cash flow outflow widened to $22.95M from $20.24MWatch
- Margins — Operating margin contracted 1883 bps to -188.25%Watch
- Accounting — Going-concern warningWatch
- Insiders — 0 purchases and 0 salesNote
Where the revenue comes from
Fiscal 2025, as CapsoVision, Inc reports it. History and quarterly detail are in the app.
- Products$14.5M
- Services$916K
Leadership changes
From CapsoVision, Inc's own filings, the day they're filed.
- David Stanley Shields · director · departureeff. 2026-07-01
- David Garcia · principal financial officer · appointmenteff. 2025-11-03
- Rebecca Petersen · Director · departureeff. 2025-10-15
Latest filings
- 8-K · Company announcement2026-08-18
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CapsoVision, Inc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.